SG11202111672RA - Cancer associated antibody compositions and methods of use - Google Patents

Cancer associated antibody compositions and methods of use

Info

Publication number
SG11202111672RA
SG11202111672RA SG11202111672RA SG11202111672RA SG11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA
Authority
SG
Singapore
Prior art keywords
methods
cancer associated
antibody compositions
associated antibody
compositions
Prior art date
Application number
SG11202111672RA
Other languages
English (en)
Inventor
Daniele Biasci
Goran Rakocevic
Berke Cagkan Toptas
Santiago Domingos De Jesus Ines De
Original Assignee
Target Discovery Merger Sub Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Target Discovery Merger Sub Ii Llc filed Critical Target Discovery Merger Sub Ii Llc
Publication of SG11202111672RA publication Critical patent/SG11202111672RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202111672RA 2019-04-30 2020-04-29 Cancer associated antibody compositions and methods of use SG11202111672RA (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201962840640P 2019-04-30 2019-04-30
US201962840638P 2019-04-30 2019-04-30
US201962840880P 2019-04-30 2019-04-30
US201962840893P 2019-04-30 2019-04-30
US201962841047P 2019-04-30 2019-04-30
US201962840855P 2019-04-30 2019-04-30
US201962841036P 2019-04-30 2019-04-30
US201962841049P 2019-04-30 2019-04-30
US201962840864P 2019-04-30 2019-04-30
US201962840917P 2019-04-30 2019-04-30
US201962840904P 2019-04-30 2019-04-30
US201962841044P 2019-04-30 2019-04-30
US201962840957P 2019-04-30 2019-04-30
US201962840870P 2019-04-30 2019-04-30
US201962840909P 2019-04-30 2019-04-30
US201962840970P 2019-04-30 2019-04-30
US201962840861P 2019-04-30 2019-04-30
US201962840875P 2019-04-30 2019-04-30
US201962840860P 2019-04-30 2019-04-30
US201962840858P 2019-04-30 2019-04-30
US201962840950P 2019-04-30 2019-04-30
US201962840938P 2019-04-30 2019-04-30
US201962840644P 2019-04-30 2019-04-30
US201962840648P 2019-04-30 2019-04-30
PCT/US2020/030534 WO2020223392A2 (en) 2019-04-30 2020-04-29 Cancer associated antibody compositions and methods of use

Publications (1)

Publication Number Publication Date
SG11202111672RA true SG11202111672RA (en) 2021-11-29

Family

ID=73029242

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111672RA SG11202111672RA (en) 2019-04-30 2020-04-29 Cancer associated antibody compositions and methods of use

Country Status (8)

Country Link
US (1) US20220204643A1 (zh)
EP (1) EP3962953A4 (zh)
JP (1) JP2022530667A (zh)
CN (1) CN114127114A (zh)
AU (1) AU2020266560A1 (zh)
CA (1) CA3138550A1 (zh)
SG (1) SG11202111672RA (zh)
WO (1) WO2020223392A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553890A (ja) * 2020-12-07 2023-12-26 アブサイ コーポレーション 疾患関連タンパク質組成物を産生するためのシステム及び方法
EP4291232A2 (en) * 2021-02-12 2023-12-20 Merck Sharp & Dohme LLC Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof
WO2024086754A2 (en) * 2022-10-19 2024-04-25 Tentarix Biotherapeutics, Inc. Multi variable domain therapeutic immunoglobulin
CN117186218B (zh) * 2023-09-06 2024-04-30 十堰市太和医院（湖北医药学院附属医院） 一种靶向rbm47的纳米抗体及其制备方法
CN117625626B (zh) * 2024-01-25 2024-04-16 中国农业科学院植物保护研究所 RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127051B2 (en) * 2010-06-09 2015-09-08 Queen Mary & Westfield College, University Of London Annexin 1 antibody
AU2012301664A1 (en) * 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
EP3892293A1 (en) * 2013-06-10 2021-10-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
US11040111B2 (en) * 2014-03-03 2021-06-22 Academia Sinica Bi-specific antibodies and uses thereof
CA3185253A1 (en) * 2015-02-02 2016-08-11 Children's Health Care D/B/A Children's Minnesota Anti-surrogate light chain antibodies
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
DK3661954T3 (da) * 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling

Also Published As

Publication number Publication date
WO2020223392A2 (en) 2020-11-05
JP2022530667A (ja) 2022-06-30
EP3962953A2 (en) 2022-03-09
CN114127114A (zh) 2022-03-01
WO2020223392A3 (en) 2020-12-10
US20220204643A1 (en) 2022-06-30
AU2020266560A1 (en) 2021-11-25
CA3138550A1 (en) 2020-11-05
EP3962953A4 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
IL288754A (en) Preparations and methods for cancer immunotherapy
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
SG11202111672RA (en) Cancer associated antibody compositions and methods of use
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL278772A (en) Antibodies against 40-OX and methods of use
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL287282A (en) Anti-mertk antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Preparations and methods of use
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL291730A (en) Protein-macromolecule conjugates and methods for using them
IL280280A (en) Formulations of FCRN antibodies and methods of using them
IL285247A (en) Improved nitrate rents and methods of their use
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL283076A (en) Methods and preparations for cancer immunotherapy
IL276203A (en) Compounds and methods for treating cancer
SG11202106295WA (en) Compositions and methods for cancer therapy
IL288886A (en) Antibodies and methods of use
IL289335A (en) New cancer antigens and methods
IL289334A (en) New cancer antigens and methods
IL289200A (en) New cancer antigens and methods
IL289205A (en) New cancer antigens and methods